Icon Bioscience Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 13

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $32M

Icon Bioscience General Information

Description

Developer of a bio-pharma platform designed to deliver injectable ophthalmic drug-device combination therapeutics. The company's bio-pharma platform focuses on the development and commercialization of novel intraocular therapeutics based on proprietary and patented drug delivery platform, enabling the healthcare professionals to experience a transformational change in the delivery of ophthalmic pharmaceuticals and address the unmet or under-satisfied ophthalmic pharmaceutical needs.

Contact Information

Formerly Known As
Icon Biosciences Inc
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 39899 Balentine Drive
  • Suite 200
  • Newark, CA 94560
  • United States
Primary Industry
Drug Delivery
Other Industries
Therapeutic Devices
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 39899 Balentine Drive
  • Suite 200
  • Newark, CA 94560
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Icon Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 28-Mar-2018 $32M Completed Profitable
3. Later Stage VC 01-Dec-2015 Completed Profitable
2. Later Stage VC (Series B) 28-Aug-2013 $15M $32M Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A) 19-Sep-2007 $17M $17M Completed Startup
To view Icon Bioscience’s complete valuation and funding history, request access »

Icon Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Icon Bioscience’s complete cap table history, request access »

Icon Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a bio-pharma platform designed to deliver injectable ophthalmic drug-device combination therapeutics. The c
Drug Delivery
Newark, CA
13 As of 2013

Bedford, MA
 

Rockville, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Icon Bioscience Competitors (8)

One of Icon Bioscience’s 8 competitors is Ocular Therapeutix, a Formerly VC-backed company based in Bedford, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ocular Therapeutix Formerly VC-backed Bedford, MA
Regenxbio Formerly VC-backed Rockville, MD
Clearside Biomedical Formerly VC-backed Alpharetta, GA
Novo Nordisk Corporation Bagsvaerd, Denmark
Revance Therapeutics Private Equity-Backed Nashville, TN
You’re viewing 5 of 8 competitors. Get the full list »

Icon Bioscience Patents

Icon Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019218870-A1 Systems, kits and methods for loading and delivering a small volume dose from a syringe Active 09-Feb-2018
AU-2019218870-B2 Systems, kits and methods for loading and delivering a small volume dose from a syringe Active 09-Feb-2018
CA-3088420-A1 Systems, kits and methods for loading and delivering a small volume dose from a syringe Pending 09-Feb-2018
EP-3749386-A2 Systems, kits and methods for loading and delivering a small volume dose from a syringe Active 09-Feb-2018
EP-3749386-A4 Systems, kits and methods for loading and delivering a small volume dose from a syringe Active 09-Feb-2018 A61M5/31541
To view Icon Bioscience’s complete patent history, request access »

Icon Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Icon Bioscience Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Signet Healthcare Partners Growth/Expansion Minority
To view Icon Bioscience’s complete investors history, request access »

Icon Bioscience FAQs

  • When was Icon Bioscience founded?

    Icon Bioscience was founded in 2004.

  • Where is Icon Bioscience headquartered?

    Icon Bioscience is headquartered in Newark, CA.

  • What is the size of Icon Bioscience?

    Icon Bioscience has 13 total employees.

  • What industry is Icon Bioscience in?

    Icon Bioscience’s primary industry is Drug Delivery.

  • Is Icon Bioscience a private or public company?

    Icon Bioscience is a Private company.

  • What is the current valuation of Icon Bioscience?

    The current valuation of Icon Bioscience is .

  • What is Icon Bioscience’s current revenue?

    The current revenue for Icon Bioscience is .

  • How much funding has Icon Bioscience raised over time?

    Icon Bioscience has raised $37.3M.

  • Who are Icon Bioscience’s investors?

    Signet Healthcare Partners has invested in Icon Bioscience.

  • Who are Icon Bioscience’s competitors?

    Ocular Therapeutix, Regenxbio, Clearside Biomedical, Novo Nordisk, and Revance Therapeutics are some of the 8 competitors of Icon Bioscience.

  • When was Icon Bioscience acquired?

    Icon Bioscience was acquired on 28-Mar-2018.

  • Who acquired Icon Bioscience?

    Icon Bioscience was acquired by EyePoint.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process